Bone Biologics Q3 Loss Narrows to $618K; $6.1M Cash Funds Operations Into Q2 2027
BBLG is trading near its 52-week low of $0.37 (1.9% above the low) on light trading volume (0.1× avg).
Summary
Bone Biologics narrowed its Q3 2026 net loss to $617,651 and held $6.1 million in cash, enough to fund operations into Q2 2027 — but the going-concern warning stands and Nasdaq's $1 bid-price deadline is March 9, 2027.
Key Events · Earnings and Guidance · BBLG
-
Q3 Loss Narrows to $618K
Net loss was $617,651 ($0.17 per share) versus $666,737 ($0.37 per share) in Q3 2025; nine-month loss fell to $2,157,341 from $2,424,348.
-
Cash of $6.1M, Runway to Q2 2027
Cash rose to $6,088,085 from $5,334,322 at December 31, 2025, funded largely by the July 2026 private placement's $2,639,667 net proceeds; management expects it to fund operations through Q2 2027 against $6.0 million of planned twelve-month spend.
-
Going Concern Doubt Reaffirmed
Accumulated losses reached $90.3 million and the filing states substantial doubt about the ability to continue as a going concern within one year, echoing the auditor's explanatory paragraph in the 2025 10-K.
-
Nasdaq Bid-Price Deadline March 9, 2027
The September 10, 2026 notice gives 180 days to regain the $1.00 minimum bid; the board holds stockholder approval for a 1-for-2 to 1-for-10 reverse split, and the new $5 million market-value rule remains stayed pending SEC review.
Analysis · BBLG · Industrial Applications And Services
The quarter improved modestly — net loss fell to $617,651 from $666,737 a year earlier and nine-month operating cash burn eased to $1.85 million from $1.98 million — but the core fact is unchanged: the company still carries an explicit substantial-doubt going-concern warning and estimates $6.0 million of operating spend over the next twelve months against $6.1 million of cash. That runway, stated through Q2 2027, depends on the July 2026 private placement, which also locked the company out of variable-rate financings other than the Wainwright ATM until July 24, 2027 and bars a reverse split without purchaser consent unless Nasdaq listing requires it. With the stock at $0.377 and a September 10, 2026 Nasdaq bid-price notice giving until March 9, 2027 to regain $1.00, the board's approved 1-for-2 to 1-for-10 reverse split is the main lever left. The warrant liability move to $198 from $703 is a non-cash mark-to-market gain, not new dilution or cash.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBLG was trading at $0.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1M. The 52-week trading range was $0.37 to $2.39. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.